The drug is designed to treat active rheumatoid arthritis and comes under a category of disease modifying anti-rheumatic drugs (DMARDS).
The clinical studies demonstrate that Iremod can relieve symptoms caused by active rheumatoid arthritis.
Simcere Pharmaceutical Group chairman and CEO Ren Jinsheng said they will continue to put their efforts and resources into developing and producing medicines for patients.